Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.

With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.

Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.

Gianfranco Nazzi will be taking over as head of the Spanish company shortly and the Barcelona-based firm's prospects look good as its dermatology portfolio and pipeline blossom.